NY-DILIGENT
10.8.2021 13:47:07 CEST | Business Wire | Press release
Diligent Corporation , the global leader in SaaS governance, risk and compliance (GRC), announced today the launch of the marketplace’s most comprehensive ESG software solution – Diligent ESG – on its governance, risk, and compliance (GRC) platform. Diligent ESG is powered in part by the newly announced acquisition of Accuvio and builds on the company’s recent acquisitions of Galvanize and Steele Compliance.
Diligent’s holistic, purpose-built ESG platform will empower organizations to address the seminal components of ESG that matter most to their stakeholders as they strive to meet current reporting requirements while also planning and preparing for the future. The solution will act as a nexus for ESG data from diverse sources to support goal setting, risk monitoring and stakeholder reporting, including to the board of directors, across diversity, climate, workforce safety, third-party risk, cyber, and more.
“Leaders today face an uphill battle in trying to establish impactful ESG programs and demonstrate progress: lack of clarity around where to start, manual processes with data in disparate systems, and a fragmented reporting landscape,” said Brian Stafford, CEO of Diligent. “Now, they can count on Diligent’s agile platform to track their risk, compliance, and ESG data in one place, establish ESG targets, and implement the governance structures to achieve those targets. With a comprehensive ESG solution at their fingertips, our clients will be able to respond with confidence to evolving regulations and investor preferences through a broader GRC practice.”
“It’s no secret that current business information systems are not designed with ESG reporting in mind,” said Matt DiGuiseppe, head of Diligent’s ESG Center of Excellence. “We are excited to offer a solution that can transform information scattered across even the most complex multinational organizations into a comprehensive, actionable ESG dataset, leverages mature capabilities battle-tested for over 30 years in the audit and compliance world.”
With Diligent ESG, public and private organizations – regardless of where they are in their program maturity – will have a sophisticated solution to help them build and enhance their ESG program, evaluate and track progress toward their goals, and integrate the data into their corporate strategy. Key features and functionality will include:
- Automated data collection through robotic process automation that connects to multiple internal platforms and monitors performance against ESG objectives in real time
- Collection, calculation, and reporting of greenhouse gas (GHG) emissions across the entire value chain (scopes, 1, 2, and 3) – all in a way that is completely auditable
- Customizable reports and real-time dashboards support clear, consistent communication with internal and external stakeholders, including regulators, focused on ESG performance
- Seamless connection of internal ESG data with third-party data, facilitating benchmarking relative to peers and the market
- Validation of how ESG programs are impacting public sentiment and assessing governance practices and executive compensation against a database of global peers, leveraging Diligent’s data and analytics
To learn more about the Diligent ESG solution, visit: https://diligent.com/solutions/esg
About Diligent Corporation
Diligent is the leading governance, risk and compliance (GRC) SaaS provider, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics and compliance across the organization. Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005588/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
